CKLife Sciences Group Limited ("CKLife Sciences") announced on August 6, 2024, the preliminary review results of its unaudited interim financial statements for the six months ended June 30, 2024. The company expects a significant decrease in the attributable profit to shareholders for the period compared to the same period of the previous year, mainly due to the sustained high financial costs. Although the health product business remains stable, the agriculture-related business is under pressure. CKLife Sciences will announce more detailed mid-term performance on August 13, 2024. The company secretary, Yang Yizhi, issued this announcement on behalf of the Board of Directors and reminded shareholders and potential investors to exercise caution when buying or selling the company's shares.

CKLife Sciences Group Limited ("CKLife Sciences") announced on August 6, 2024, the preliminary review results of its unaudited interim financial statements for the six months ended June 30, 2024. The company expects a significant decrease in the attributable profit to shareholders for the period compared to the same period of the previous year, mainly due to the sustained high financial costs. Although the health product business remains stable, the agriculture-related business is under pressure. CKLife Sciences will announce more detailed mid-term performance on August 13, 2024. The company secretary, Yang Yizhi, issued this announcement on behalf of the Board of Directors and reminded shareholders and potential investors to exercise caution when buying or selling the company's shares.